Northwestern Mutual Wealth Management Co. cut its stake in shares of Eli Lilly And Co (NYSE:LLY) by 2.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 61,109 shares of the company’s stock after selling 1,226 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Eli Lilly And Co were worth $8,476,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. Pacitti Group Inc. bought a new position in shares of Eli Lilly And Co in the fourth quarter valued at about $25,000. Stonebridge Financial Planning Group LLC raised its holdings in shares of Eli Lilly And Co by 70.0% in the first quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock valued at $25,000 after buying an additional 70 shares during the last quarter. Sugarloaf Wealth Management LLC bought a new position in shares of Eli Lilly And Co in the fourth quarter valued at about $26,000. Truvestments Capital LLC bought a new position in shares of Eli Lilly And Co in the first quarter valued at about $27,000. Finally, Solstein Capital LLC bought a new position in shares of Eli Lilly And Co in the fourth quarter valued at about $34,000. 77.98% of the stock is owned by institutional investors and hedge funds.
In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $139.11, for a total value of $29,213,100.00. Following the completion of the transaction, the insider now directly owns 113,441,468 shares in the company, valued at approximately $15,780,842,613.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Aarti S. Shah sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $150.00, for a total value of $300,000.00. Following the completion of the transaction, the senior vice president now owns 19,087 shares of the company’s stock, valued at $2,863,050. The disclosure for this sale can be found here. Insiders sold a total of 906,320 shares of company stock valued at $132,984,238 over the last quarter. 0.09% of the stock is owned by insiders.
Eli Lilly And Co stock opened at $151.16 on Friday. The firm has a market capitalization of $145.65 billion, a P/E ratio of 24.99, a PEG ratio of 1.82 and a beta of 0.25. Eli Lilly And Co has a 1 year low of $101.36 and a 1 year high of $164.90. The business has a 50-day moving average of $152.85 and a 200-day moving average of $136.00. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 4.37.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Thursday, April 23rd. The company reported $1.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. The company had revenue of $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. During the same period in the previous year, the company earned $1.33 EPS. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year. Research analysts anticipate that Eli Lilly And Co will post 6.81 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a $0.74 dividend. The ex-dividend date is Thursday, May 14th. This represents a $2.96 annualized dividend and a dividend yield of 1.96%. Eli Lilly And Co’s dividend payout ratio is presently 49.01%.
A number of research firms recently issued reports on LLY. Barclays began coverage on Eli Lilly And Co in a report on Thursday, February 27th. They issued an “overweight” rating for the company. Goldman Sachs Group raised Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 price target for the company in a report on Wednesday, March 11th. Zacks Investment Research dropped their price objective on Eli Lilly And Co to $156.00 in a report on Wednesday, April 29th. Mizuho boosted their price objective on Eli Lilly And Co from $148.00 to $155.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Finally, UBS Group cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $157.00 to $158.00 in a report on Monday, April 20th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $158.64.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.